Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants orphan drug status to OSE-2101

Feb. 18, 2013

177Lu-J-591 shows promising antitumor activity at the MTD of 70 mCi/m2

Feb. 18, 2013

Roche presents potential predictivity of preclinical cancer models

Feb. 18, 2013

Peregrine Pharmaceuticals reports results from phase II bavituximab trial

Feb. 14, 2013

ImmunoGen achieves patient enrollment milestone in phase II NORTH trial

Feb. 13, 2013

TG Therapeutics opens expansion cohorts in trial of ublituximab

Feb. 12, 2013

First patient treated in phase I trial of GL-ONC1

Feb. 7, 2013

Seattle Genetics begins two phase I trials of SGN-CD19A

Feb. 7, 2013

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Feb. 7, 2013

Health Canada grants approval to Adcetris for two lymphoma indications

Feb. 4, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
Gensci-134: a long-acting growth hormone receptor agonist fusion protein
BioWorld Science
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone...